F atty liver disease is becoming increasingly common both in the United States and worldwide because of changing lifestyles. (1) (2) (3) (4) (5) It encompasses liver injury ranging from steatosis to severe steatohepatitis that can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma in a subgroup of patients. (6, 7) However, natural history remains incompletely understood, and patients with advanced liver fibrosis have the highest risk of progressing to endstage liver disease. (6, (8) (9) (10) (11) (12) (13) (14) In a recent multicenter prospective study of nonalcoholic fatty liver disease (NAFLD) patients, fibrosis stage was the only histological feature independently associated with liverrelated events, liver transplantation, and overall mortality. (15) Currently, the gold standard for diagnosis and staging of liver fibrosis is liver biopsy. However, liver biopsy cannot be performed on the general population for steatosis and fibrosis prevalence estimation.
The increasing burden of chronic liver disease and need for risk stratification and continual disease monitoring to better personalize treatment has led to the evaluation of clinical measures as noninvasive markers of liver fibrosis, including imaging methods that use transient elastography to measure liver stiffness and serum markers that directly measure components of extracellular matrix or indirectly measure hepatic damage and/or dysfunction during development of fibrosis. Scoring systems derived from commonly measured serum markers of hepatic dysfunction include the aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis-4 (FIB-4) score, and Forns score, which were originally developed in patients with chronic hepatitis C virus infection and have subsequently been used with other liver diseases, including NAFLD. (16) (17) (18) (19) (20) (21) (22) (23) Recently, the NAFLD fibrosis score (NFS) was specifically constructed to predict advanced fibrosis in NAFLD patients. (24) These scoring systems have been shown to identify histological fibrosis with reasonable accuracy in cross-sectional studies. However, little is known about the role of fibrosis scores in natural history and prognosis, particularly their ability to predict adverse hepatic outcomes among asymptomatic persons, including those with NAFLD at high risk of progression. (25) In a previous paper using the third National Health and Nutrition Examination Survey (NHANES III) population with mortality followup through 2006, fibrosis predicted by NFS, APRI, or FIB-4 score was independently associated with increased mortality, primarily from cardiovascular disease, among persons with suspected NAFLD. (26) At the time of those earlier analyses, the number of deaths from liver disease was too small to provide reliable estimates. We questioned whether recent survey-linked National Death Index records with 5 additional years of follow-up would reveal a stronger relationship of fibrosis scores with mortality outcomes, including liver disease mortality. Mortality ascertainment is now complete for NHANES III through 2011, providing up to 23 years of follow-up. We examined whether APRI, FIB-4 score, NFS, and Forns score were associated with increased overall and disease-specific mortality among persons without viral hepatitis in this national, population-based, prospective survey.
Materials and Methods
NHANES III was conducted in the United States from 1988 through 1994 by the National Center for Health Statistics of the Centers for Disease Control and Prevention. (27) The survey consisted of crosssectional interview, examination, and laboratory data collected from a complex multistage, stratified, clustered probability sample representative of the civilian, noninstitutionalized population with oversampling of non-Hispanic blacks, Mexican Americans, and persons aged 60 years or older. The survey was approved by the Centers for Disease Control and Prevention ethics review board, and all participants provided written informed consent to participate. Data were collected at baseline on factors believed to be related to liver injury and used to calculate fibrosis scores and/or included as covariates in multivariate analyses (28) (29) (30) : age, sex, race/ethnicity, education, alcohol intake, cigarette smoking, caffeine intake from beverages, physical activity, diagnosed diabetes, body mass index (kg/m 2 ); waist-to-hip circumference ratio, and systolic and diastolic blood pressure. A venous blood sample was collected and shipped weekly at 2208C to testing laboratories. Aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, albumin, platelet count, hepatitis B virus surface antigen, hepatitis C virus RNA, transferrin saturation, and concentrations of hemoglobin A 1C , total and highdensity lipoprotein cholesterol, C-reactive protein, alkaline phosphatase, and total bilirubin were measured as described previously. (31) Diabetes was defined as a health care provider diagnosis or hemoglobin A 1C 6.5% and prediabetes as hemoglobin A 1C 5.7%-<6.5%.
Four scores-APRI, FIB-4, NFS, and Forns-were calculated as described previously (Table 1) . (16, 19, 22, 24) The originally described cut-points for each score were used to categorize liver fibrosis probability as low, intermediate, or high (Table 1) . (18, 19, 22, 32) For APRI, intermediate and high categories were combined because of low liver disease mortality numbers in the NHANES III study sample representative of the United States general population.
Of 23,258 sampled persons aged 20 years and older in NHANES III, 16,573 (71%) attended a study visit at a mobile examination center. Participants were excluded if they were positive for serum hepatitis B surface antigen or hepatitis C RNA (n 5 346). We additionally excluded persons who were missing data on viral hepatitis serology (n 5 1084) or fibrosis score components (APRI and FIB-4, n 5 279; NFS, n 5 379), were ineligible for mortality follow-up (n 5 12), or did not have a cause of death available (n 5 11), resulting in analysis samples of 14,841 for APRI and FIB-4 and 14,741 for NFS. One component of the Forns score, gamma glutamyltransferase, was added to the protocol after the beginning of the survey (n 5 3531 missing), resulting in an analysis sample of 11,589 (Fig. 1 ).
Participants were passively followed for mortality through December 31, 2011, by linking NHANES III with National Death Index records through a probabilistic match, a well-established and validated matching method. (33, 34) Mortality outcomes were based on death certificate underlying or contributing cause coded according to the International Classification of Diseases, Ninth Revision (ICD-9) for deaths occurring between 1988 and 1998 and the International Classification of Characteristics of participants by fibrosis score categories were examined by comparing the mean (standard deviation) of continuous factors using analysis of variance and percentages of categorical factors using a chi-square test. Unadjusted cumulative mortality during follow-up by fibrosis score category was calculated using Kaplan-Meier analysis. Hazard ratio (HR) estimates (relative risk) and 95% confidence intervals (CIs) for mortality outcomes were calculated using Cox proportional hazard regression analysis (SUDAAN PROC SURVIVAL) to control for effects of potential risk factors while taking into consideration varying lengths of follow-up. Factors included in multivariate analyses consisted of age, sex, race/ethnicity, education level, alcohol intake, cigarette smoking, caffeine intake from beverages, physical activity, body mass index, waist-to-hip circumference ratio, diabetes, total and high-density lipoprotein cholesterol, systolic and diastolic blood pressure, C-reactive protein, and transferrin saturation. Continuous factors whose distributions were skewed to the right were categorized as deciles (10 th percentiles) in regression models. HRs were computed for intermediate and high fibrosis score categories relative to the low category. Time at risk was from the date of the NHANES III examination to the date of death or to December 31, 2011. For analyses of cause-specific mortality, participants who died from other causes were censored at the date of death. All factors met the proportional hazard assumption of a relatively constant risk ratio through examination oflog (-log) plots of survival versus time by categories. (36) Multivariate analyses excluded persons with missing values for any factor included in the model. P values were two-sided, and a P value of <0.05 was considered to indicate statistical significance. All analyses used sample weights that accounted for unequal selection probabilities and nonresponse. All variance calculations accounted for design effects of the survey using Taylor series linearization.
(37)
Results
Distributions of APRI, FIB-4 score, NFS, and Forns score among NHANES III participants without viral hepatitis are shown by fibrosis score category in Table 2 . Using originally described cut-points, prevalence of an intermediate and high fibrosis score varied (Table 2 ). In general, persons with higher scores had more adverse liver-related characteristics (Table 3) . They were also older, less educated, and more likely to be obese, diabetic, and hypertensive, with higher Creactive protein and lower caffeine intake (Table 3) . Relationships with sex, race/ethnicity, alcohol consumption, cigarette smoking, physical activity, lipid levels, and transferrin saturation varied among fibrosis scores.
MORTALITY FOLLOW-UP
The median follow-up time was 19.3 years (interquartile range, 17.5-21.1 years). The cumulative mortality from all causes was 28.0% (4835 deaths) at 23 years of follow-up. The cause-specific cumulative mortality (underlying or contributing cause) was 11.4% (1993 deaths) with cardiovascular disease, 9.0% (1216 deaths) with neoplasms, 3.4% (593 deaths) with diabetes, and 0.82% (151 deaths) with liver disease, including primary liver cancer.
FIBROSIS SCORES AND LIVER DISEASE MORTALITY
For mortality overall and from each specific cause, unadjusted cumulative mortality rates were greater, with higher fibrosis scores (Table 4) . For liver disease mortality, intermediate and high fibrosis scores were associated with increased risk in age-adjusted analysis (Table 4) . With multivariate adjustment, liver disease mortality remained elevated with an intermediate to (Figs. 2E and 3) . If liver disease mortality was defined based on underlying cause of death alone, rather than on any of the multiple causes recorded on the death certificate, there were 90 deaths. Similar to the main analysis, liver disease mortality risk was increased with intermediate and high fibrosis scores in unadjusted, age-adjusted, and multivariate-adjusted analyses; however, for intermediate levels, some hazard ratios did not reach statistical significance due to smaller numbers of liver disease deaths (data not shown). When participants with viral hepatitis were included in analyses, there were 209 deaths with liver disease as the underlying or contributing cause. Similar to the main analysis, liver disease mortality risk was increased with intermediate and high APRI, FIB-4 score, and Forns score in unadjusted, age-adjusted, and multivariate-adjusted analyses, and most relationships were stronger than in the main analysis due to the larger number of liver disease deaths (data not shown). The NFS, which was developed specifically for NAFLD, was not analyzed when persons with viral hepatitis were included.
Mortality from all causes was greater among persons with an intermediate to high APRI, high FIB-4 score, and intermediate or high NFS or Forns score when adjusted for age (Table 4) . With multivariate adjustment, mortality risk was higher for an intermediate to high APRI (HR, 1.39; 95% CI, 1.08-1.79), intermediate (HR, 1.11; 95% CI, 1.01-1.22) or high (HR, 1.56; 95% CI, 1.29-1.88) FIB-4 score, high NFS (HR, 1.39; 95% CI, 1.20-1.60), and high Forns score (HR, 1.57; 95% CI, 1.19-2.08) (Fig. 2A) . When participants with viral hepatitis were included in analyses, there were 5386 deaths from all causes. The results were similar to those of the main analysis (data not shown).
Cardiovascular disease mortality was increased with a high FIB-4 or Forns score or intermediate or high NFS in age-adjusted analyses (Table 4) . In multivariate-adjusted analyses, an association remained only with a high FIB-4 score (HR, 1.56; 95% CI, 1.17-2.08) (Fig. 2B) . Mortality from neoplasms was higher with an intermediate to high APRI or high NFS or Forns score in age-adjusted analyses (Table 4) , and the risk remained with an intermediate to high APRI in multivariate-adjusted analyses (HR, 1.67; 95% CI, 1.13-2.45) (Fig. 2C) (Fig. 2D) . Results for cardiovascular disease, neoplasms, and diabetes mortality were similar to those of the main analysis when outcomes were limited to underlying cause of death (data not shown) or when participants with viral hepatitis were included (data not shown).
Discussion
In this United States population-based study with up to 23 years of follow-up, intermediate to high liver fibrosis scores among persons without viral hepatitis were associated with increased liver disease mortality. This relationship was consistent in age-and multivariateadjusted analyses and across four fibrosis scores, both nonspecific and specific for NAFLD. Intermediate to high fibrosis scores were also associated with increased overall mortality in age-and multivariate-adjusted analyses. Associations with higher mortality from cardiovascular disease, neoplasms, and diabetes were found inconsistently across fibrosis scores.
Fibrosis scores have been shown to predict histological fibrosis with reasonable accuracy in cross-sectional studies. (16) (17) (18) (19) (20) (21) (22) (23) (24) Fibrosis scores may also be useful as prognostic tools among persons with NAFLD, but this approach has been studied less. Hepatic steatosis on ultrasound and elevated liver enzyme activities as noninvasive markers of fatty liver or nonalcoholic steatohepatitis have been examined in relation to disease outcome, including mortality. (38, 39) However, few prospective studies of fibrosis scores have been well-powered to predict liver disease mortality and other long-term adverse hepatic outcomes. (40) (41) (42) A previous analysis of the NHANES III population with mortality follow-up through 2006 found higher overall and cardiovascular disease mortality in association with three of the same fibrosis scores among persons with suspected NAFLD. (26) Higher liver disease mortality was not reported in that analysis, which had shorter follow-up and fewer liver-related deaths. In an international multicenter study of 320 biopsydiagnosed NAFLD patients followed for a median of 8.7 years, fibrosis scores, including NFS, APRI, and FIB-4, identified patients at increased risk for liverrelated complications, all-cause mortality, and liver transplantation. (40) In a community-based study of 302 NAFLD patients identified through the Rochester Epidemiology Project and followed for a mean of 12 years, a higher NFS at baseline was predictive of increased overall mortality risk. (41) The latter two studies demonstrated that fibrosis scores predicted all-cause mortality, but neither was large enough to investigate disease-specific mortality. We are unaware of other well-powered prospective studies of prognostic ability of fibrosis scores in NAFLD patient cohorts or the general population.
A diagnosis of NAFLD requires exclusion of significant alcohol intake (>21 drinks on average per week for men or >14 drinks on average per week for women). (43) However, because over two thirds of adults in the United States are now overweight or obese, mixed forms of NAFLD and alcoholic fatty liver disease are increasingly likely. (44, 45) Furthermore, the accuracy of self-reported alcohol consumption is unknown and clinical diagnosis based on patient-reported intake remains a potential source of misclassification between modest and significant alcohol use. In this analysis, we did not exclude persons based on their reported alcohol consumption; instead, we adjusted for alcohol intake in multivariate analyses to present a more comprehensive picture of the fatty liver disease epidemic. Furthermore, because characteristic features of nonalcoholic steatohepatitis, such as steatosis and inflammation, may diminish as fibrosis progresses, we did not limit our analysis to persons with steatosis on ultrasound and/or elevated liver enzymes, but studied the entire NHANES III population who were negative for viral hepatitis markers. (46, 47) A limitation of using NHANES III to study fibrosis scores is reliance on single measurements of serum markers without a histological diagnosis. However, liver biopsies cannot be conducted on the general population. Imaging methods that use transient elastography to measure liver stiffness and serum markers that directly measure components of extracellular matrix may be more accurate than indirect serum markers, but were not performed in NHANES III. In addition, the scoring systems we studied provide a qualitative, not quantitative measure of fibrosis, and have not been validated in the general population. However, these fibrosis scores have been validated in patients with viral hepatitis, alcoholic liver disease, NAFLD, and other diseases.
Furthermore, a recent report suggested that the performance of the NFS and FIB-4 score for identifying and excluding advanced fibrosis may vary across the life span, with lower accuracy among young adults and lower specificity among older adults. (48) Another limitation of our study was lack of validation of cause of death. Although ascertainment of vital status using the National Death Index is high (>99%), assigning cause of death based on death certificate diagnoses can lead to misclassification. Finally, because participants were not reevaluated during follow-up, some may have developed increased fibrosis, leading to misclassification. However, we hypothesize that an increase in fibrosis scores would lead to a stronger association with liver disease mortality. Likewise, we did not obtain any longitudinal data on changes in other baseline participant characteristics, which could lead to misclassification during the follow-up period. Assuming this misclassification was nondifferential among study participants, our results may be skewed toward null and underestimate the strength of the associations of liver fibrosis scores with mortality outcomes. These limitations are balanced by the benefits of a representative population-based sample, particularly avoidance of ascertainment bias found in clinical studies of conveniently selected patients, and ability to generalize results to the United States population. Other important strengths were over two decades of mortality follow-up and availability of data on numerous predictors of liver disease mortality measured at baseline.
In conclusion, in the United States population, intermediate to high liver fibrosis scores were associated with increased liver disease mortality. Higher overall mortality was also associated with elevated fibrosis scores; however, relationships were inconsistent with mortality from cardiovascular disease, neoplasms, and diabetes. A 2012 American Gastroenterological Association practice guideline on the diagnosis and management of NAFLD recommended the clinical use of the NFS for identifying NAFLD patients with higher likelihood of having bridging fibrosis and/or cirrhosis. (43) Our study provides support for the use of fibrosis scores, including the NFS, for identifying persons at high risk for advanced fibrosis. (25, 49) Therefore, liver health management with fibrosis risk stratification merits further investigation with serial monitoring and targeted interventions.
